SCHEDULE 13D/A: SCHEDULE 13D/A – Description
Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for…
Allogene Therapeutics Announces Participation in September Investor Conference
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for…
SCHEDULE 13G/A: SCHEDULE 13G/A – Description
Allogene Therapeutics, Inc.
S-3: Simplified registration form
Allogene Therapeutics, Inc.
- 1
- 2
- 3
- 4
- 5
- Go to the next page